1. ATHENA-HF
Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone (n = 178).
Results
(p = 0.57)
Primary outcome, log change in NT-proBNP at 96 hours: in the spironolactone group vs in the placebo group (p = 0.57)
Net urine output: 6.1 L in the spironolactone group vs. 5.6 L in the placebo group (p = 0.57)
Conclusions
Among patients admitted with acute heart failure, high-dose spironolactone was not effective at reducing NT-proBNP levels
Secondary outcomes, including urine output, were also similar between treatment groups
-0.49
-0.55
Spironolactone
Control
Presented by Dr. Javed Butler at AHA 2016